Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTorresi, Josephen
dc.contributor.authorMcCarthy, Karenen
dc.contributor.authorFeroldi, Emmanuelen
dc.contributor.authorMéric, Claudeen
dc.date.accessioned2015-05-16T00:43:18Z
dc.date.available2015-05-16T00:43:18Z
dc.date.issued2010-10-08en
dc.identifier.citationVaccine 2010; 28(50): 7993-8000en
dc.identifier.govdoc20934459en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11134en
dc.description.abstractJapanese encephalitis chimeric virus vaccine (JE-CV) was developed to replace licensed mouse brain-derived vaccine (MBD-JE), the production of which ceased in 2005. Two randomised controlled phase 3 studies were conducted. Immunogenicity study: 410 participants received one JE-CV injection, 410 received 3 MBD-JE injections. Safety study: 1,601 participants received JE-CV, 403 received placebo. Seroconversion after a single JE-CV vaccination (99.1%) was statistically non-inferior to that after three-dose MBD-JE (95.1%) vaccination. JE-CV elicited a rapid immune response, with 93.6% of participants seroconverting within 14 days. Adverse reaction rates were significantly lower with JE-CV (67.6%) than with MBD-JE (82.2%) (p<0.001), and the reactogenicity profile of JE-CV was comparable with that of placebo. A single dose of JE-CV elicited rapid seroconversion in a higher proportion of vaccinees than the current vaccine with fewer reactions. The safety profile of JE-CV is good.en
dc.language.isoenen
dc.subject.otherAdolescenten
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAntibodies, Neutralizing.blooden
dc.subject.otherAntibodies, Viral.blooden
dc.subject.otherDouble-Blind Methoden
dc.subject.otherEncephalitis, Japanese.prevention & controlen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherJapanese Encephalitis Vaccines.administration & dosage.adverse effects.immunologyen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherNeutralization Testsen
dc.subject.otherVaccines, Attenuated.administration & dosage.adverse effects.immunologyen
dc.subject.otherYoung Adulten
dc.titleImmunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.en
dc.typeJournal Articleen
dc.identifier.journaltitleVaccineen
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1016/j.vaccine.2010.09.035en
dc.description.pages7993-8000en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/20934459en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.